IL317395A - Compositions containing disodium 10,5-methylene-(6R)-tetrahydrofolate - Google Patents
Compositions containing disodium 10,5-methylene-(6R)-tetrahydrofolateInfo
- Publication number
- IL317395A IL317395A IL317395A IL31739524A IL317395A IL 317395 A IL317395 A IL 317395A IL 317395 A IL317395 A IL 317395A IL 31739524 A IL31739524 A IL 31739524A IL 317395 A IL317395 A IL 317395A
- Authority
- IL
- Israel
- Prior art keywords
- methylene
- tetrahydrofolic acid
- disodium salt
- lyophilized composition
- citrate
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1611—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Inorganic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Dermatology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP22177932 | 2022-06-08 | ||
| PCT/EP2023/064972 WO2023237484A1 (en) | 2022-06-08 | 2023-06-05 | Compositions comprising disodium 5,10-methylene-(6r)-tetrahydrofolate |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL317395A true IL317395A (en) | 2025-02-01 |
Family
ID=81984853
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL317395A IL317395A (en) | 2022-06-08 | 2023-06-05 | Compositions containing disodium 10,5-methylene-(6R)-tetrahydrofolate |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20250360135A1 (cg-RX-API-DMAC10.html) |
| EP (2) | EP4706775A3 (cg-RX-API-DMAC10.html) |
| JP (1) | JP7894470B2 (cg-RX-API-DMAC10.html) |
| KR (1) | KR20250022145A (cg-RX-API-DMAC10.html) |
| CN (1) | CN119365186A (cg-RX-API-DMAC10.html) |
| AU (1) | AU2023282347A1 (cg-RX-API-DMAC10.html) |
| CA (1) | CA3258734A1 (cg-RX-API-DMAC10.html) |
| ES (1) | ES3069418T3 (cg-RX-API-DMAC10.html) |
| IL (1) | IL317395A (cg-RX-API-DMAC10.html) |
| PL (1) | PL4536187T3 (cg-RX-API-DMAC10.html) |
| WO (1) | WO2023237484A1 (cg-RX-API-DMAC10.html) |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1215945A (en) | 1983-03-20 | 1986-12-30 | Bengt Gustavsson | Fluid transfer system |
| CH682664A5 (en) | 1991-10-15 | 1993-10-29 | Eprova Ag | Stable salts of 5,10-methylene tetrahydrofolate. |
| ATE262799T1 (de) * | 1996-01-31 | 2004-04-15 | Univ South Alabama | Lebensmittel und vitamin herstellungen mit natürlichem isomeren von reduzierten folaten |
| CH696628A5 (de) | 2002-02-26 | 2007-08-31 | Eprova Ag | Verwendung von Folaten zur Herstellung einer Zubereitung geeignet zur Vorbeugung und Behandlung von Entzündungen und entzündungsassoziierter Krankheiten, im Speziellen zur Beeinflussung der |
| CH697021A5 (de) * | 2003-06-26 | 2008-03-31 | Merck Eprova Ag | Stabile pharmazeutische Zusammensetzungen von 5, 10-Methylentetrahydrofolat. |
| WO2007064968A2 (en) | 2005-12-02 | 2007-06-07 | Adventrx Pharmaceuticals, Inc. | Stable pharmaceutical compositions of 5,10 methylenetetrahydrofolate |
| JP6235779B2 (ja) | 2012-03-28 | 2017-11-22 | 株式会社コーセー | 葉酸含有組成物及び葉酸の安定化方法 |
| EP2799061A1 (en) | 2013-04-30 | 2014-11-05 | Aprofol AG | Stable high dose pharmaceutical composition containing folates |
| EP2837631A1 (en) | 2013-08-14 | 2015-02-18 | Merck & Cie | New stable salt of 5,10-methylene-(6R)-tetrahydrofolic acid |
| US10059710B2 (en) * | 2016-02-17 | 2018-08-28 | Merck & Cie | Stable formulations of 5,10-methylene-(6R)-tetrahydrofolic acid |
| PT3668516T (pt) * | 2017-08-16 | 2021-12-23 | Merck Patent Gmbh | Liofilizados estáveis que compreendem ácido 5,10-metileno-(6r)-tetra-hidrofólico e um ácido dicarboxílico |
| CN107892692A (zh) * | 2017-12-28 | 2018-04-10 | 华东理工大学 | (6s)‑5‑甲基四氢叶酸锌盐的制备方法及其应用 |
-
2023
- 2023-06-05 WO PCT/EP2023/064972 patent/WO2023237484A1/en not_active Ceased
- 2023-06-05 CA CA3258734A patent/CA3258734A1/en active Pending
- 2023-06-05 ES ES23730517T patent/ES3069418T3/es active Active
- 2023-06-05 EP EP26153960.5A patent/EP4706775A3/en active Pending
- 2023-06-05 EP EP23730517.2A patent/EP4536187B1/en active Active
- 2023-06-05 US US18/872,672 patent/US20250360135A1/en active Pending
- 2023-06-05 KR KR1020257000562A patent/KR20250022145A/ko active Pending
- 2023-06-05 AU AU2023282347A patent/AU2023282347A1/en active Pending
- 2023-06-05 PL PL23730517.2T patent/PL4536187T3/pl unknown
- 2023-06-05 IL IL317395A patent/IL317395A/en unknown
- 2023-06-05 CN CN202380045351.1A patent/CN119365186A/zh active Pending
- 2023-06-05 JP JP2024570947A patent/JP7894470B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP4536187C0 (en) | 2026-01-28 |
| EP4536187B1 (en) | 2026-01-28 |
| EP4706775A2 (en) | 2026-03-11 |
| EP4536187A1 (en) | 2025-04-16 |
| PL4536187T3 (pl) | 2026-05-04 |
| CA3258734A1 (en) | 2023-12-14 |
| WO2023237484A1 (en) | 2023-12-14 |
| AU2023282347A1 (en) | 2025-01-16 |
| EP4706775A3 (en) | 2026-06-10 |
| JP7894470B2 (ja) | 2026-07-23 |
| KR20250022145A (ko) | 2025-02-14 |
| CN119365186A (zh) | 2025-01-24 |
| ES3069418T3 (en) | 2026-06-08 |
| US20250360135A1 (en) | 2025-11-27 |
| JP2025518274A (ja) | 2025-06-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0401895B1 (en) | Aqueous folinate solution stable at refrigerator temperature, as well as process for its preparation | |
| US3957980A (en) | Doxycycline parenteral compositions | |
| US4126680A (en) | Tetracycline antibiotic compositions | |
| US20230233464A1 (en) | Methotrexate Composition | |
| US20160030573A1 (en) | Stable pharmaceutical compositions of 5,10-methylenetetrahydrofolate | |
| AU709785B2 (en) | Stable solutions of 2-chloro-2'-deoxyadenosine formulations | |
| RU2012147527A (ru) | Тетрациклиновая композиция | |
| JPH02273623A (ja) | ダプトマイシン希釈製剤 | |
| US20040170701A1 (en) | Pharmaceutical composition comprising copper, salicylic acid, vitamin c and zinc for use in treatment of different diseases such as bacterial or viral infection | |
| US12622913B2 (en) | Folate salts for medical use | |
| EP0801571B1 (en) | Soluble 2-chloro-2'-deoxyadenosine formulations | |
| SK287547B6 (sk) | Farmaceutické činidlo, ktoré obsahuje ako aktívnu zložku derivát benzamidu | |
| KR20050106119A (ko) | 항종양 효과 증강제 및 항종양제 | |
| KR920004098B1 (ko) | 레베카마이신 동족체의 안정 용액 및 그의 제조방법 | |
| US6613767B1 (en) | Stable aqueous folinate solution | |
| US3335055A (en) | More stable and more soluble tetracycline compositions suitable for parenteral use and method of preparing same | |
| JPH0517355A (ja) | 点眼剤 | |
| EP0427078A1 (en) | Folinic acid-cyclodextrin inclusion compound | |
| US3155587A (en) | Stable liquid preparations of 7-chlorotetracycline | |
| US5075295A (en) | Novel oxytetracycline compositions | |
| JP2025518274A5 (cg-RX-API-DMAC10.html) | ||
| JP3122921B2 (ja) | ビオチン含有内用液剤 | |
| AU762821B2 (en) | 'Soluble 2-chloro-2'-deoxyadenosine formulations' | |
| US4833132A (en) | Process for treating a warm-blooded animal with an antineoplastic/antime-tastatic effective composition | |
| CN119343131A (zh) | 包含5,10-亚甲基-(6r)-四氢叶酸钠的浓缩溶液 |